Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives

Abstract

Post-cycle therapy (PCT) refers to the use of pharmacological agents – most commonly selective estrogen receptor modulators (SERMs), human chorionic gonadotropin (hCG), and aromatase inhibitors (AIs) – after cessation of androgen abuse to accelerate recovery of the hypothalamic–pituitary–gonadal (HPG) axis. Exogenous androgens suppress endogenous testosterone production through negative feedback, often resulting in a transient hypogonadal state that may persist for weeks to months, and occasionally longer, depending on cycle characteristics and individual factors. The rationale of PCT is to mitigate this suppression and reduce symptoms of androgen deficiency. However, evidence supporting its use is limited, with most data derived from observational studies or extrapolated from other forms of secondary hypogonadism. While some studies suggest that PCT may accelerate short-term hormonal and seminal recovery, spontaneous recovery occurs in the majority of individuals within months after cessation. Three perspectives can be distinguished. In real-world practice, PCT is widely used, often without medical supervision, driven by cultural norms and concerns about symptom persistence. From an academic standpoint, PCT is generally not recommended because of uncertain benefits and potential risks. A third perspective describes a pragmatic rationale for considering a short course of PCT in carefully selected individuals with significant symptom burden or risk of relapse into androgen abuse, while acknowledging that this approach is not supported by robust clinical evidence. This review aims to clarify the rationale, evidence gaps, and clinical implications of these perspectives to support informed clinical decision-making.